Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89–IgA and IgG–IgA complexes: common mechanisms for distinct diseases  by Tissandié, Emilie et al.
see commentary on page 1252
Both IgA nephropathy and alcoholic cirrhosis feature
abnormally glycosylated IgA1 and soluble CD89–IgA
and IgG–IgA complexes: common mechanisms for
distinct diseases
Emilie Tissandie´1,2, Willy Morelle3,8, Laureline Berthelot1,2,8, Franc¸ois Vrtovsnik1,2,4, Eric Daugas1,2,4,
Francine Walker2,5, Didier Lebrec2,5,6, Jean-Marie Trawale´2,5,6, Claire Francoz2,5, Franc¸ois Durand2,5,6,
Ivan C. Moura1,2, Vale´rie Paradis2,5,7, Richard Moreau2,5,6 and Renato C. Monteiro1,2
1Inserm U699, Paris, France; 2Site Bichat, Faculte´ de Me´decine, Universite´ Paris Diderot, Paris, France; 3Unite´ Mixte de Recherche
CNRS/USTL 8576, IFR 147, Universite´ des Sciences et Technologies de Lille 1, Villeneuve d’Ascq, France; 4Service de Ne´phrologie,
Hoˆpital Bichat-Claude Bernard, Paris, France; 5Inserm U773, Centre de Recherche Biome´dicale Bichat-Beaujon CRB3, Paris, France;
6Service de He´patologie, Hoˆpital Beaujon, Assistance Publique Hoˆpitaux de Paris, Clichy, France and 7Service d’Anatomie-Pathologique,
Hoˆpital Beaujon, Assistance Publique Hoˆpitaux de Paris, Clichy, France
Abnormalities of IgA arise in alcoholic cirrhosis, including
mesangial IgA deposits with possible development of
secondary IgA nephropathy (IgAN). Since little is known
about circulating immune complexes in cases of secondary
IgAN, we analyzed IgA-associated parameters in the serum of
32 patients with compensated or advanced alcoholic cirrhosis.
Galactose deficiency and decreased sialylation of IgA1, as well
as increased amounts of abnormally glycosylated polymeric
IgA1, were detected in the serum of patients with advanced
alcoholic cirrhosis. Moreover, aberrant IgA1 formed
complexes with IgG and soluble CD89 in serum of patients
with advanced alcoholic cirrhosis, similar to those found in
primary IgAN. The IgA1 of alcoholic cirrhosis, however, had a
modified N-glycosylation, not found in primary IgAN.
In patients with alcoholic cirrhosis and IgAN, IgA deposits
were associated with CD71 overexpression in mesangial
areas, suggesting that CD71 might be involved in deposit
formation. Although the IgA1 found in alcoholic cirrhosis
bound more extensively to human mesangial cells than
control IgA1, they differ from primary IgAN by not inducing
mesangial cell proliferation. Thus, abnormally glycosylated
IgA1 and soluble CD89–IgA and IgA–IgG complexes, features
of primary IgAN, are also present in alcoholic cirrhosis. Hence,
common mechanisms appear to be shared by diseases of
distinct origins, indicating that common environmental
factors may influence the development of IgAN.
Kidney International (2011) 80, 1352–1363; doi:10.1038/ki.2011.276;
published online 24 August 2011
KEYWORDS: alcoholic cirrhosis; glycosylation; IgA; nephropathy; receptors
Alterations of immunoglobulin (Ig)A metabolism in alco-
holic cirrhosis (AC) have been described since three decades.1
This disease has been considered as an IgA-associated
disorder.2 IgA dysfunctions in AC are mainly characterized
by an enhancement of serum IgA levels involving both forms,
polymeric and monomeric IgA, and by deposits of IgA in
tissues in a granular pattern predominantly in the glomerular
mesangium3 and more rarely in the hepatic sinusoids and the
capillaries of skin and jejunum.4 In somes cases, overt
secondary IgA nephropathy (IgAN) can be clinically observed
with progression to renal failure, which are often a problem
for liver transplantation indication requiring the need of an
associated renal allograft.5 Both IgA1 and IgA2 subclasses
are also elevated in the serum of AC patients.6 Secretory
IgA (SIgA), a product generated by epithelial cells after
transcytosis of dimeric IgA and cleavage of the poly-Ig
receptor,7 is also elevated in serum of patients with cirrhosis1
but not explored in tissues. Factors involved in increased
levels of IgA in serum of cirrhotic patients have been
explored. They include increased IgA synthesis8 and defective
clearance of IgA and IgA-circulating immune complexes
(IgA–CIC) due to a impairment in expression and glycosyla-
tion of CD89 (type 1 IgA Fc receptor or FcaRI) on blood
monocytes of AC patients.9 Recently, it has been shown that
Toll-like receptor-9 priming of B cells accounts for the hyper-
IgA levels observed in serum of cirrhotic patients, suggesting
that an increase in IgA synthesis may be due to bacterial
translocation and/or infections.10 IgA-containing immune
complexes (IgA–CIC) have indeed been observed in the
serum and kidneys of AC patients,11 although no evidence
has been found for bacterial components in these CIC.
Moreover, the mechanisms by which IgA abnormalities in
cirrhosis can lead to tissue IgA deposits causing secondary
IgAN remain unknown, and little is known on the nature of
intrinsic alterations of IgA in cirrhosis. It is important to note
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that IgAN is the commonest nephropathy in patients with
cirrhosis.3,12 It may progress to chronic kidney disease and
hence have a major impact on prognosis.12 Therefore, more
information is needed on intrinsic alterations of IgA and
their role in the development of IgAN in cirrhosis.
Structural alterations of IgA system have a major role in
primary IgAN.13 The underlying pathogenic mechanism in
primary IgAN involves immune complexes and abnormal
glycosylation of IgA1.14–17 Oligosaccharides have an impor-
tant role in structure and function of immunoglobulins.
Sugars are essential for stability, resistance to proteases, and
quaternary structure of immunoglobulins, as well as for
interactions of antibodies with others molecules.18,19 In
contrast to IgA2, IgA1 is the most glycosylated form, mainly
due to the attachment of O-linked glycans in their hinge
region to serine or threonine residues. In primary IgAN, IgA1
abnormalities result in increased exposure of terminal
N-acetylgalactosamine (GalNAc) residues because of the lack
of galactose and sialic acid residues.20,21 This defect in IgA1
glycosylation generates neoepitopes that are recognized by
naturally occurring IgG and IgA antibodies with anti-hinge
region specificity.22 Such alterations induce the formation of
undergalactosylated IgA1-IC that are deposited in the
mesangium.20 Abnormal IgA also induces the release of
soluble FcaRI (CD89) from blood myeloid cells, leading to
the formation and amplification of the size of circulating
IgA-IC.23 In addition, altered glycosylation of IgA1 causes an
increased expression of the mesangial transferrin receptor
(CD71) mediating mesangial deposition of nephritogenic
IgA1-IC.24–26 All these data suggested that the composition of
IgA1 hinge-region glycans in primary IgAN is implicated in
the mechanism of IgA1 deposition and in the development of
glomerular injury. Although abnormally glycosylated IgA1 in
primary IgAN and their pathogenic role in renal injury has
been the subject of extensive investigations,13 IgA and CIC
properties in cirrhosis remain largely unexplored.
The identification of intrinsic IgA abnormalities in patients
with AC is essential to understand the molecular mechanisms
involved in the secondary IgAN to develop new treatments to
prevent progression to renal failure. Comparison of IgA
abnormalities in patients with alcoholic cirrhosis and primary
IgAN patients is expected to reveal critical features commonly
shared by these pathologies, and therefore important for their
onset and progression. The aim of the study was to analyze
glycosylation of IgA1, as well as to characterize CIC components
in patients with alcoholic cirrhosis according to the severity of
liver disease. Additional experiments were conducted comparing
certain aspects of structural alterations of IgA1 between cirrhosis
with secondary IgAN and primary IgAN notably in their ability
to bind mesangial cells and to induce cell proliferation.
RESULTS
Identification of hypogalactosylation and hyposialylation
of serum IgA1 in patients with advanced alcoholic cirrhosis
As expected,27 IgA and SIgA concentrations were increased in
serum from patients with compensated and advanced
cirrhosis as compared with those from controls (Supple-
mentary Figure S1 online). To study the O-glycosylation
profile of IgA1, we used the helix aspersa (HAA)-binding
assay, a lectin specific for GalNAc, and mass spectrometry.
Binding of the HAA lectin to serum IgA1 from patients with
advanced cirrhosis was higher than to those from healthy
controls (0.484±0.054 vs. 0.232±0.021; P¼ 0.001; Figure
1a), indicating an increase in GalNAc structure. In contrast,
no modification of HAA lectin binding was observed for
compensated cirrhosis. These findings suggested a galactose
deficiency in the hinge-region O-linked glycans of IgA1 of
advanced cirrhosis but not of compensated cirrhosis. We
therefore analyzed O-glycosylation pattern of jacalin-purified
IgA1 from patients with cirrhosis and patients with primary
IgAN using matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF-MS). Mass spectra
showed a higher level of signal intensity for galactosylated
GalNAc glycan (m/z¼ 534) in AC and primary IgAN patients
compared with healthy controls corresponding to a decreased
amount of sialylated glycans (Figure 1b and Supplementary
Figure S2 online). This glycosylation analysis showed a defect
in galactosylation and sialylation of IgA1, which was more
pronounced in advanced than in compensated cirrhosis or
primary IgAN. It has to be noted that MALDI-TOF-MS
applied to permethylated O-glycans is unable to detect
any structure corresponding to O-GalNAc at theoretical
m/z¼ 330. Because of the high volatility of the methylated
derivative, this compound was probably lost during
the purification step. Consequently, mass spectrometry
and HAA-binding assay pointed to two O-glycosylation
defects in advanced cirrhosis. Size of serum IgA was then
analyzed by immunoblotting after SDS-polyacrylamide gel
electrophoresis separation under nonreducing conditions
(Figure 2a). Densitometric analyses of the blots showed an
increased proportion of polymeric and dimeric IgA in
patients with advanced and compensated cirrhosis compared
with control subjects (Figure 2b). To determine the molecular
form of abnormally glycosylated IgA1, fractions obtained
from size-exclusion chromatography were analyzed for their
content in IgA reacting with HAA (Figure 2c). In patients
with advanced cirrhosis, IgA binding to HAA was increased
in low- and in high-molecular-weight forms of IgA as
compared with those of control subjects (Figure 2c).
Abnormal N-glycosylation of serum IgA1 in patients
with alcoholic cirrhosis
As N-glycans are important for the biological action of
immunoglobulins and are increased in IgA of cirrhotic
patients,28 we studied N-glycosylation of purified IgA1 from
patients with cirrhosis by MALDI-TOF-MS. Mass spectra
showed that N-glycosylation profiles of compensated and
advanced cirrhosis IgA1 are different from that of healthy
controls and primary IgAN patients (Figure 3 and Supple-
mentary Figure S3 online). Indeed, ions at m/z¼ 1907
(Hex3HexNAc5) and 2111 (Hex4HexNAc5), which corre-
spond to asialylated structures, were more intense for the two
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Figure 1 | Serum immunoglobulin (Ig)A is abnormally glycosylated in patients with alcoholic cirrhosis (AC). O-glycosylation profile of serum
IgA1 was studied by HAA-ELISA and by mass spectrometry. (a) The levels of HAA binding were higher in patients with advanced AC (mean±s.d.;
0.484±0.054) compared with patients with compensated AC (0.225±0.058), as well as with healthy controls (0.232±0.021), using sera normalized
at 10mg/ml of IgA. Each group, n¼ 12–20. ****Po0.0001. The results are expressed as optical density (OD) measured at 405nm. (b) The analysis
by matrix-assisted laser desorption ionization time-of-flight mass spectrometry of O-linked glycans of IgA1 isolated by jacalin-affinity
chromatography showed higher levels of signal intensity for galactosylated N-acetylgalactosamine (GalNAc) glycan (m/z¼ 534) in AC and primary
IgA nephropathy (IgAN) patients compared with healthy controls, corresponding to decreased amounts of sialylated glycans. Representative
mass spectra observed in two or three patients and healthy controls are shown (see other mass spectra in Supplementary Figure S2 online).
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groups of patients with cirrhosis than for the other groups. In
addition, the ion at m/z¼ 2792 (NeuAc2Hex5HexNAc4),
which corresponds to a bisialylated biantennary structure,
was reduced in intensity only for patients with advanced
cirrhosis. These modifications were not observed in primary
IgAN patients.
CICs from patients with advanced alcoholic cirrhosis contain
aberrant glycosylated IgA1, IgG anti-IgA antibodies, and
soluble CD89–IgA complexes
Because CIC-containing aberrantly glycosylated IgA1 have
an important role in the pathogenesis of primary IgAN,13
the composition of IgA1-containing CICs was investigated in
patients with cirrhosis. Serum CICs were isolated by
polyethylene glycol precipitation and their contents were
analyzed by ELISA at equal total protein concentration.
Patients with advanced, but not compensated, cirrhosis had
high concentrations of IgA and SIgA in CICs compared with
small amounts detected in CICs from healthy controls
(198.60±29.39 vs. 15.02±3.76 ng/ml; Po0.0001 and
20.36±3.18 vs. 0.04±0.03 ng/ml; Po0.0001; Figure 4a and
b). A significant correlation was found between biochemical
values (serum albumin and bilirubin concentrations, as well
as prothrombin time) and the IgA and SIgA levels present in
CICs in patients with cirrhosis (data not shown), indicating
that increased IgA- and SIgA-CICs concentrations are corr-
elated with the severity of cirrhosis. The levels of IgA–IgG and
particularly IgA1–IgG complexes were increased in polyethylene
glycol precipitates of patients with advanced cirrhosis compared
with controls (0.722±0.022 vs. 0.450±0.043; Po0.0001 and
0.485±0.058 vs. 0.290±0.031; Po0.05, respectively), whereas
no difference was observed in SIgA–IgG complex levels (Figure
4c–e). Thus, circulating IgA1, but not SigA, induce IgG–anti-IgA
response forming immune complexes in secondary IgAN. In
addition, IgA–CICs of advanced AC patients with advanced
cirrhosis contained galactose-deficient O-linked glycans as
demonstrated by HAA lectin binding (Figure 5).
As soluble IgA receptor CD89 (FcaRI) may have an important
role in the development of primary IgAN by formation of
circulating IgA-soluble CD89 complexes,23,24 we next analyzed
the presence of such complexes in the CICs of patients with
cirrhosis. IgA-soluble CD89 complex levels were found to be
markedly increased in polyethylene glycol precipitates of patients
with compensated and advanced cirrhosis as compared with
those of healthy subjects (0.089±0.017 and 0.379±0.110 vs.
0.023±0.004; Po0.01 and Po0.0001, respectively; Figure 4f). In
parallel, CD89–IgA1 interaction was studied by ELISA using
soluble recombinant CD89 and by flow cytometry using rat
basophilic leukemia transfected with human CD89 (Supple-
mentary Figure S4 online). ELISA analysis showed that binding
of IgA1 from patients with advanced cirrhosis to CD89 was
significantly higher than that of IgA1 from control subjects
(Supplementary Figure S4a and b online). This was confirmed by
flow cytometry analysis (Supplementary Figure S4c online).
CD71 IgA receptor is overexpressed by mesangial cells
and is not associated with mesangial proliferation in
kidneys from patients with IgA nephropathy and advanced
alcoholic cirrhosis
To study renal consequences of IgA deposits, six patients with
cirrhosis and biopsy-proven secondary IgAN were studied.
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Figure 2 |Polymeric and monomeric immunoglobulin (Ig)A are
abnormally glycosylated. (a) Molecular form of IgA contained in
total serum of compensated and advanced alcoholic cirrhosis (AC)
patients and healthy controls were analyzed by immunoblotting
(IB) after SDS-polyacrylamide gel electrophoresis separation under
nonreducing conditions using a biotinylated anti-IgA antibody.
Molecular-weight markers are indicated on the left side. (b) Each
lane was quantified by densitometry. AC patients presented an
increased proportion of polymeric and dimeric IgA compared with
control subjects (about 19 and 12% of IgA were, respectively,
dimeric and polymeric in serum of AC patients in contrast to only
7 and 2% in serum of healthy controls). (c) Sera from patients with
compensated AC (filled circles), patients with advanced AC (filled
squares), and healthy controls (open circles) were separated by
size-exclusion chromatography using a HiPrep 16/60 Sephacryl
S300 column. Fractions were analyzed by ELISA for the content of
IgA and IgA reacting with HAA. Molecular masses of the calibrated
column are indicated. Representative profiles observed in three
patients and healthy controls are shown in panels a, b, and c. CTL,
control; HAA, helix aspersa; OD, optical density.
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Mesangial IgA deposition is observed in kidneys of patients
with cirrhosis similar to that observed in primary IgAN
(Figure 6a). This correlates with the increased capacity of
IgA1 from patients with advanced cirrhosis to bind to
cultured human mesangial cells (HMCs) as compared with
control IgA1 (Figure 6b). Immunostaining for SIgA using an
anti-secretory component antibody was negative in renal
biopsies of patients with cirrhosis (data not shown). CD71
was overexpressed in the mesangium of glomeruli from
patients with cirrhosis (Figure 6a). The intensity of CD71
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Figure 3 |Aberrant N-glycosylation of immunoglobulin (Ig)A1 in patients with alcoholic cirrhosis (AC). The analysis by matrix-assisted
laser desorption ionization time-of-flight mass spectrometry of N-linked glycans of IgA1 isolated by jacalin-affinity chromatography
showed modifications in the level of signal intensity for various glycans (m/z¼ 1907, 1923, 2111, 2792) in patients with AC compared with
healthy controls, whereas profiles for primary IgA nephropathy (IgAN) patients and healthy controls are more similar. Representative mass
spectra observed in two or three patients and healthy controls are shown (see other mass spectra in Supplementary Figure S3 online).
CTL, control.
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staining was similar to that observed in primary IgAN
patients (Figure 6a). Next we studied the mesangial prolifer-
ation, which may occur in patients with primary IgAN.
Interestingly, only few cells were stained by Ki67 antibody
(cellular proliferation marker) in kidney biopsies from
cirrhosis, whereas multiple cells were stained by Ki67 in
primary IgAN kidney biopsies, used as control (Figure 6a).
This result was consistent with our in vitro proliferation assay
on HMC incubated with jacalin-purified IgA1 (Figure 6c).
Incubation of HMC with IgA1 from IgAN, but not from
patients with advanced AC, induced mesangial proliferation.
DISCUSSION
This study provides evidence that IgA1 antibodies from
patients with cirrhosis are abnormally glycosylated. Using
two complementary approaches, MALDI-TOF-MS and
lectin-binding assays, we show that the O-linked oligosac-
charides contain less galactose and less sialic acid residues.
This defect was more marked in patients with advanced
cirrhosis than those with compensated cirrhosis. Although
O-glycans of IgA1 from cirrhosis and primary IgAN patients
displayed a similar reduction in galactosylation and sialyla-
tion, IgA1 abnormalities from cirrhosis differ from primary
IgAN, as in cirrhosis both forms of IgA1 polymers and
monomers are abnormally O-glycosylated, whereas in
primary IgAN the HAA binding to IgA1 is observed mainly
in high-molecular-weight fractions after size-exclusion chro-
matography.22 Increase in both forms (monomers and
polymers) of circulating aberrant IgA1 in cirrhosis may be
explained by altered catabolism caused by liver failure.
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Figure 4 |Detection of increased amounts of circulating immune complexes (CICs) containing immunoglobulin (Ig)A, secretory IgA
(SIgA), IgA/IgG, and IgA/CD89 in patients with alcoholic cirrhosis (AC). Content of CICs from patients with advanced AC (filled squares,
n¼ 12), patients with compensated AC (filled circles, n¼ 20), and healthy controls (open circles, n¼ 16) was analyzed by ELISA. The levels
of IgA (a), SIgA (b), IgA/IgG (c), IgA1/IgG (e), and IgA/soluble CD89 (f) complexes in CICs from patients with advanced AC were
significantly higher than those in CICs from healthy controls. In contrast, SIgA/IgG (d) complexes levels did not differ between the
three groups. *Po0.05; **Po0.01; ****Po0.0001. Horizontal lines indicate the mean. The results are expressed as optical density (OD)
measured at 405 nm.
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Indeed, it has been demonstrated that the liver is the major
site involved in the catabolism mediated, at least partially, by
the asialoglycoprotein receptor through terminal galactose
residues,29 and clearance of both IgA1–IgG complexes and
ASGP are largely delayed in cirrhotic patients.30 Another
mechanism may explain the altered catabolism of IgA1.
Patients with cirrhosis have decreased expression of the IgA
Fc receptor, the CD89, on monocyte/macrophage surfaces31
associated with impaired CD89 endocytic function,9 which
may also contribute to the increase in the circulation of both
forms of IgA. Our results also show that aberrant glycosyla-
tion was not restricted to O-linked glycan chains, but
occurred also in N-linked glycan chains of IgA1 from
patients with cirrhosis. All cirrhotic patients analyzed in
this study presented modifications of N-glycans in IgA1.
These findings agree with a previous study showing that
fucosylation of IgA oligosaccharides changes during cirrho-
sis28 and suggest that liver disease is sufficient to induce
N-glycosylation changes. As hepatocytes have a crucial role in
blood clearance of N-linked carbohydrates bound to IgA
through asialoglycoprotein receptor,32 their loss in cirrhotic
liver may contribute to enhanced IgA1 levels in the circula-
tion of cirrhotic patients. Interestingly, modifications in
N-glycans were also observed in IgA1 from primary IgAN but
were different from the IgA1 antibodies of cirrhosis in
intensity and N-glycan chain position. Taken together,
O- and N-glycosylation aberrations in IgA1 from patients
with cirrhosis might induce changes in IgA function and
contribute directly or indirectly to the development of
secondary IgAN. The direct effect of ethanol metabolites in
altered IgA1 glycosylation cannot also be excluded as it has
been shown in animal models that chronic ethanol
consumption decreases galactosyltransferase and sialyltrans-
ferase activities.33 Interestingly, it has been shown that
alcohol intake can induce IgAN in mice.34,35
Degalactosylation and desialylation lead to increased
exposure of terminal GalNAc residues. This abnormally
glycosylated IgA1 was shown to self-aggregate and form
complexes with IgG and IgA1 antibodies specific for GalNAc
in the IgA1 hinge region.13,17 Blood levels of CIC composed
of galactose-deficient IgA1 complexed with antiglycan
antibodies are increased in primary IgAN patients.36 In the
present study, HAA lectin-binding assay showed that CICs of
severe AC patients contained galactose-deficient IgA asso-
ciated with an increased level of IgA1–IgG complexes. We
also noted a correlation between biochemical parameters
(serum albumin, bilirubin, or prothrombin time) and levels
of degalactosylated IgA1 and IgA1–IgG complexes, providing
evidence that the presence of such complexes is associated
with cirrhosis severity (data not shown). Moreover, two
populations of the patients with compensated and advanced
AC can be distinguished with high and low IgA/IgG complex
levels (see Figure 4e), indicating that some AC patients
may fail to mount an immune response to abnormal IgA1.
However, no correlations with clinical characteristics and
serum factors were observed between these two subgroups.
Interestingly, it has been observed by others that glycosylation
defect in primary IgAN is closely associated with renal disease
progression.37,38 Thus, these findings reveal that patients with
cirrhosis are prone to develop IgAN. Indeed, an impaired
renal function (proteinuria and increased levels of creatinine)
is observed in patients with advanced cirrhosis (Supplemen-
tary Table S1 online).
The increased levels of SIgA in serum and their presence in
CICs from patients with compensated and advanced cirrhosis
may suggest mucosal abnormalities in cirrhosis. Although
previous studies suggested a pathogenic role for SIgA in
glomerular injury in IgAN,39 SigA–IgG complexes were not
detected in CIC from ALC patients, suggesting that SIgA did
not induce an IgG immune response in cirrhosis. SIgA may
not be implicated in IgA deposition in the mesangium of
ALC patients as no staining was detected in renal biopsies
and anti-secretory component antibody (data not shown).
Therefore, the role of SIgA in AC remains to be elucidated.
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Figure 5 |Circulating immune complex (CIC) of patients with
alcoholic cirrhosis (AC) contains abnormally glycosylated
immunoglobulin (Ig)A. O-glycosylation profile of CIC-containing
IgA1 was studied by HAA-ELISA. The levels of HAA binding were
higher in CICs from patients with advanced AC (mean±s.d.;
0.792±0.154) compared with patients with compensated AC
(0.267±0.060), as well as with healthy controls (0.167±0.020),
using CIC samples normalized at 500mg/ml of total proteins.
Each group, n¼ 12–20; ****Po0.0001. The results are expressed as
optical density (OD) measured at 405 nm.
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Our analyses of CIC content revealed an increased
presence of IgA-soluble CD89 complexes in the serum of
the two groups of patients with cirrhosis but not in those of
control subjects. Interestingly, our previous study has
reported a decreased CD89 expression at the surface of
circulating blood monocytes from patients with cirrhosis.9
Together, these data point to a proteolytic cleavage mecha-
nism rather than to a secreted soluble form of CD89 in
cirrhosis. Whether ADAM 10 and ADAM 17 metalloprotei-
nases are involved remain to be elucidated.40 Increased IgA-
soluble CD89 complexes have been previously reported in
primary IgAN patients by our group,15,23 and have been
recently confirmed by others using the same method: A3
anti-CD89 monoclonal antibody (mAb) clone as capture
antibody and polyclonal anti-IgA antibody for detection.41
Moreover, decrease in serum levels of IgA-soluble CD89
complexes are linked to disease progression in Swedish
patients with primary IgAN.41 This is in contrast to increased
presence of IgA-soluble CD89 in serum from patients with
IgAN secondary to advanced AC, which are associated with
renal dysfunction, and may suggest different pathogenic
mechanisms between both diseases. Indeed, although patients
with AC-associated secondary IgAN present proteinuria and
renal function decline, they do not have mesangial prolifera-
tion. The presence of soluble CD89 in CICs is possibly due to
an increased affinity between aberrant glycosylated IgA1 from
patients with cirrhosis and CD89. Surface plasmon resonance
studies showed that the dissociation of monomeric IgA was
more rapid than that of polymeric IgA, explaining a more
sustained binding of the latter to CD89 (refs 39,42). More-
over, polymeric IgA contains more O-glycans than mono-
meric IgA, which are important for interaction with mesangial
cells and CD71 receptor.26,43 The increased binding capability
of the AC patient’s IgA1 to CD89 recombinant or CD89-
transfected cells obtained in vitro might be explained by the
increased proportion of polymeric IgA forms, which may
favor CD89 shedding as described in vitro.23 We cannot rule
out from our studies that alterations in N- or O-glycans
moities of the CD89 receptor of AC patients may also
influence IgA binding and receptor shedding. Indeed, our
previous work indicates that CD89 from these patients have
altered SDS-polyacrylamide gel electrophoresis mobility.9
Moreover, it has been recently shown that deglycosylation of
FcaRI increases IgA binding.44 IgA-soluble CD89 complexes
levels were markedly increased in patients with compensated
and advanced cirrhosis, suggesting that these complexes may
represent an early biomarker for the presence of AC even at
the compensated stage of the disease.
The mechanism of IgA1 deposition in the mesangium
involves IgA1 receptors.24 One of these receptors has been
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Figure 6 |Glomerular immunoglobulin (Ig)A deposition is
associated with CD71 overexpression but not mesangial cell
proliferation in patients with alcoholic cirrhosis (AC). (a) IgA,
CD71, and Ki67 immunohistochemical staining (as indicated on the
left) of kidney biopsies from patients with advanced AC and with
primary IgA nephropathy (IgAN). IgA deposits were associated
with CD71 overexpression in the mesangial area of glomeruli in
patients with AC and IgAN. Cellular proliferation was seen in
glomeruli from IgAN patients but not from patients with AC, as
indicated by stronger staining for Ki67 in the kidney of IgAN
patients compared with AC patients. Representative data observed
in four patients and healthy controls are shown. (b) Binding of
jacalin-purified IgA1 from three patients with advanced AC, three
patients with primary IgAN, and three control subjects (1mg/ml)
to human mesangial cells (HMCs) was assessed by flow cytometry.
IgA1 from patients with advanced AC and primary IgAN bound
more to HMCs than control. Mean fluorescence intensity was used
as a measure of binding (mean±s.d.) and IgG was used as
negative control. (c) Human mesangial cells were stimulated with
jacalin-purified IgA1 from three patients with advanced AC, three
patients with primary IgAN, and three control subjects (0.5mg/ml).
After 48 h, HMC proliferation was assessed using Alamar Blue
assay. IgA1 from patients with IgAN induced HMC proliferation
compared with control subjects in contrast to IgA1 from patients
with advanced AC. *Po0.05; ***Po0.01. Proliferation was
expressed as relative fluorescence intensity (mean±s.d.).
Incubation of HMCs with medium alone was used as negative
control. CTL, control; MFI, mean fluorescence intensity.
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identified as the transferrin receptor (CD71), which is
overexpressed on the mesangium in kidney biopsies from
primary IgAN patients.24,26,45 Moreover, CICs containing
galactose-deficient IgA1 from primary IgAN have been
reported to bind more efficiently to mesangial cells than
normal IgA1.46 Interestingly, our immunohistochemical
analysis indicates for the first time that CD71 expression is
also upregulated in the mesangium of patients with cirrhosis
similar to that observed in patients with primary IgAN,
suggesting that mesangial CD71 is involved in the develop-
ment of IgAN in cirrhosis. In addition, aberrant IgA1
antibodies from patients with advanced cirrhosis have
increased capacity to bind to cultured HMCs as compared
with IgA1 from healthy controls. This may explain glomer-
ular deposition of IgA1 in patients with cirrhosis similar to
the mechanism proposed in primary IgAN. Studies with
deglycosylated IgA1 revealed the major role of O-linked
rather than N-linked sugars in the interaction with CD71 or
mesangial cells.26,47 Therefore, aberrant O-glycosylation of
IgA1 from patients with cirrhosis may be implicated in IgA
deposition in their mesangium through interaction with
mesangial CD71. However, despite these mechanistic similar-
ities between primary and secondary IgAN, differences exist
between both diseases. Although primary IgAN are often
associated with mesangial proliferation,48 our patients with
AC-associated IgAN did not present proliferative character-
istics. Indeed, our immunohistochemical data showed low
staining of Ki67 in renal biopsy specimens from patients
with AC. In addition, although IgA1 from patients with
advanced cirrhosis bound more to HMCs in vitro, they did
not induce mesangial proliferation. These data suggest
that the increase in CD71 mesangial expression observed
in secondary IgAN does not result from mesangial cell
proliferation but is induced by IgA1 deposition as we
reported for primary IgAN.49 Finally, as IgA1 antibodies in
both primary IgAN and AC are abnormally O-glycosylated,
one can propose that levels of N-glycans in IgA1 may be
involved in the control of mesangial proliferation altering
CD71 function. Indeed, N-glycans in other glycoproteins
have been shown to have an essential role in exocytic and
endocytic protein trafficking.50
In conclusion, in patients with advanced cirrhosis,
defective O- and N-glycosylation of IgA1 and IgA1-contain-
ing CIC may have an important role in the pathogenesis of
secondary IgAN. Patients with compensated cirrhosis exhibit
a less marked defect in O- and N-glycosylation, suggesting
that alterations of IgA1 structure begin early in the course of
the disease. Other important findings in this study are the
presence of IgA–CD89 or IgG–IgA complexes even at the early
stage of the cirrhosis. These results open new avenues in the
development of early biomarkers of diagnostic of cirrhosis
and in the understanding of secondary IgAN due to liver
diseases. The fact that both primary IgAN and AC diseases
share common pathways involved in renal injury suggests
that common environmental factors may influence develop-
ment of IgAN in susceptible individuals.
MATERIALS AND METHODS
Patients
Patients with biopsy-proven alcoholic cirrhosis were enrolled in this
study. A total of 12 patients with compensated cirrhosis (8 men
and 4 women), 20 patients with advanced cirrhosis (14 men and
6 women), and 20 healthy volunteers (8 men and 12 women) were
studied. In this study, the severity of cirrhosis was assessed using the
well-established Child–Pugh score.51 The Child–Pugh score ranges
from 5 to 15, with a score of 5 or 6 representing class A (compen-
sated cirrhosis), 7 to 9 class B (moderate cirrhosis), and 10 to 15
class C (advanced cirrhosis). In our study, we enrolled Child–Pugh
class A or C patients but not class B patients. None of the patients
had ongoing bacterial infection. Clinical characteristics of the
patients are reported in Supplementary Table S1 online. Six patients
with cirrhosis and biopsy-proven secondary IgAN and six patients
with primary IgAN were studied for immunostaining experiments
in renal biopsies. Informed written consent was obtained from each
patient and healthy volunteer. This study was approved by the Local
Ethics Committee of Beaujon Hospital.
Cells
HMCs were purchased from Clonetics (San Diego, CA) and
were cultured in an RPMI 1640 medium (Invitrogen, Cergy
Pontoise, France) supplemented with glutamine (2 mM), insulin
(5mg/ml), penicillin (50 U/ml), streptomycin (50mg/ml; Sigma,
Saint Quentin Fallavier, France), and 20% fetal calf serum (PAA
laboratories, Les Mureaux, France). Cells were used at fourth to
seventh passages. Rat basophilic leukemia cells (RBL2H3), trans-
fected with human CD89,52 were maintained in Dulbecco’s modied
Eagle’s medium supplemented with glutamine (2 mM), penicillin
(50 U/ml), streptomycin (50 mg/ml), 10% fetal calf serum, and G418
(1.0 mg/ml; PAA laboratories).
CIC precipitation
Serum CICs were isolated using polyethylene glycol precipitation
as described.23 The final protein concentration was determined
using a NanoDrop Spectrophotometer (Nanodrop Technologies,
Wilmington, DE).
Measurement of immunoglobulins and antibodies
IgA and SIgA concentration in sera and CICs were determined by a
sandwich ELISA. Briefly, microtitration plates (BD, Le Pont
de Claix, France) were coated with 10 mg/ml F(ab’)2 fragment of
goat anti-human IgA (Clinisciences, Montrouge, France) or with
10 mg/ml sheep anti-human secretory component chain (Abcam,
Cambridge, UK). Samples were revealed with a monoclonal anti-
human IgA alkaline phosphatase (AP) conjugate (BD). The optical
density (OD) at 405 nm was measured after addition of
streptavidin-AP substrate (Sigma). The test sera diluted to 1:100
and CICs at a concentration of 250 mg/ml were added to the wells.
Samples were incubated either with anti-human IgA or IgG AP
conjugate (BD), or with sheep anti-human IgA secretory
chain, followed by incubation with anti-sheep IgG AP conjugate
(Clinisciences).
Measurement and analysis of CICs
Levels of IgA/IgG, IgA1/IgG, SIgA/IgA, and IgA/soluble CD89
complexes in CICs were determined by ELISA. Microtitration plates
were coated with 10 mg/ml F(ab’)2 fragment of goat anti-human
IgA (for cross-capture of IgA–IgG complexes) or 10 mg/ml mouse
anti-human IgA (BD; for cross-capture of IgA1/IgG complexes) or
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10 mg/ml sheep anti-human IgA secretory chain (for cross-capture
of SIgA/IgG complexes) or 10 mg/ml mouse anti-CD89 mAbs A3,53
(for cross-capture of IgA/soluble CD89 complexes), as described.23
Test CICs were added at a concentration of 10 mg/ml and incubated
with rabbit anti-human IgG (Hþ L) AP conjugate (Clinisciences)
for the detection of IgA/IgG and SIgA/IgG complexes and with anti-
human IgA AP conjugate for the detection of IgA-soluble CD89
complexes. The OD at 405 nm was measured after addition of
streptavidin-AP substrate.
Analysis of IgA molecular forms
Molecular size of serum IgA was studied by immunoblotting and by
size-exclusion chromatography. Diluted sera (1:100) were separated
on 6% SDS-polyacrylamide gels and blotted onto polyvinylidine
difluoride membrane (Millipore, Guyancourt, France). IgA were
detected with a biotinylated anti-IgA mAb and a streptavidin-
horseradish peroxidase (Clinisciences). Blots were developed using
an enhanced chemiluminescence detection system (VWR, Fontenay
sous Bois, France). To examine the molecular size of IgA1 proteins
reacting with HAA lectin, sera from patients with compensated AC,
advanced AC, and control subjects were applied to a HiPrep 16/60
Sephacryl S300 (GE Healthcare, Saclay, France) equilibrated in
phosphate-buffered saline and fractioned. Each fraction was
analyzed by ELISA for the content of IgA and IgA reacting with
HAA as described above.
IgA purification
IgA1 from sera of patients with AC and control subjects was purified
by ammonium sulfate precipitation and jacalin-affinity chromato-
graphy as described previously,26 as this method has been proved
to be efficient for purifying proteins bearing O-linked oligo-
saccharides.54 The total protein concentration of the sample was
measured using NanoDrop Spectrophotometer. Purity was assessed
by SDS-polyacrylamide gel electrophoresis analysis.
Evaluation of IgA1 binding to CD89
Binding of IgA1 to CD89 was analyzed by ELISA and flow
cytometry. First, soluble CD89 and IgA1 complexes were prepared
by incubating 5 mg/ml of soluble CD89 with 5 mg/ml of purified IgA1
for 1 h at 37 1C. Microtitration plates were coated with 10 mg/ml of
mouse anti-CD89 mAbs A3, soluble CD89, and IgA1 complexes
were added to the wells and incubated overnight at 4 1C. After
washing, bound IgA1 antibodies were detected with anti-human IgA
AP conjugate. The OD at 405 nm was measured after addition of
streptavidin-AP substrate and was used as a measure of binding.
Second, IgA1 binding to Rat basophilic leukemia cells (RBL3H3)
transfected with human CD89 was studied by flow cytometry.
Briefly, rat basophilic leukemia-expressing CD89 (0.25 106) were
incubated with purified IgA1 (0.5 mg/ml) for 1 h at 4 1C. After
washing, cells were stained with a biotinylated anti-IgA mAb (BD)
for 30 min. The IgA1 binding was revealed by adding allophycocya-
nin-labeled straptavidin and analyzed by flow cytometry using a
FACScalibur (BD).
Analysis of O-glycosylation by a lectin assay
The glycan content of serum IgA1 and CICs-containing IgA1 was
tested by ELISA using HAA (Sigma), a well-known lectin able to
bind to terminal GalNAc residues, as described.21 This assay was
performed in the absence of neuraminidase treatment. The serum
and CIC samples were adjusted to 10 mg/ml of IgA and 500 mg/ml of
total proteins, respectively, in microtitration plates. The lectin
reactivity was expressed as OD unit.
Release, preparation, and mass spectrometry analysis of
glycans
Purified IgA was reduced and carboxyamidomethylated, followed
by sequential tryptic and peptide N-glycosidase F digestion and
Sep-Pak purification as described previously.55 Putative O-glyco-
peptides remaining after PNGase F-digestion of the tryptic
glycopeptides were subjected to reductive elimination as described
previously.56 Permethylation of the freeze-dried glycans, sample
clean-up, and MALDI-TOF-MS analysis of permethylated glycans
were performed as described elsewhere.57
Evaluation of mesangial IgA1 binding and mesangial
proliferation
IgA1 binding to HMCs was determined using an indirect
immunofluorescence assay as described earlier.26 For proliferation
experiment, HMCs were starved for 24 h and purified IgA1
antibodies were added at 0.5 mg/ml for 12 h. The culture medium
alone was used as negative control. Alamar Blue (Invitrogen) was
added to the culture media at 10% of the media volume for 24 h.
Fluorescence intensity was measured using a microplate reader.
Immunohistochemistry
IgA, transferrin receptor (CD71), and Ki-67 expression were
examined on 4-mm paraffin or frozen sections of renal tissue. After
the avidin/biotin blocking steps, slices were immersed in normal
horse serum (Thermo Scientific, Courtaboeuf, France) to block
nonspecific sites. Samples were stained with a biotinylated anti-
human IgA (BD), with a biotinylated anti-human transferrin receptor
(Clinisciences), or with a rabbit anti-Ki-67 (Thermo Scientific),
followed by incubation with biotinylated goat anti-rabbit IgG (Hþ L;
BD). Slides were then developed using avidin-conjugated horseradish
peroxidase with diaminiobenzidine as substrate (Dako, Trappes,
France) and were counterstained with hematoxylin.
Statistical analyses
All values are reported as mean±s.e.m. Student’s unpaired t-test
and the Mann–Whitney U-test were used for statistical comparisons.
Linear regression analysis was carried out to investigate correla-
tion between clinical characteristics of the patients and serum
data. P values equal or less than 0.05 were considered statistically
significant. All statistical analyses were performed with GraphPad
Prism version 5 (GraphPad Software, San Diego, CA).
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